NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Scott H. Davis who wrote (357)	2/3/1999 12:27:00 AM
From: Steve Lokness	Read Replies (1) of 613

I don't know about others, but I'm a real believer in pharmacogenomics as well as a true believer in AXPH. AXPH believes they can become king of the biotechs and I believe as long as Walker remains at the helm that it could happen. Share price was creamed when AXPH picked up SQNA, but todays news looks to be just one of the positives that SQNA brought to the merger. Looks like a win win for AXPH. They get upfront license fee, lots of "stuff" from PPDI and a majority ownership plus PPDI provides financing! Wow! You have to assume that AXPH is also in first position to take advantage of information as it develops. Talk about your undervalued companies! Are there comments as to how the AXPH pharmacogenomics business might stack up against GLGC and CRGN? Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next